In this review paper, researchers present the current preclinical approaches used in immuno-oncology for solid tumors and their underlying challenges. They found that a majority of these approaches used cell-to-cell interactions and cell migration (36%) rather than looking at the effects of specific immunotherapy agents. ACT therapies (33%), ICB (11%), antibodies (8%), DC vaccines (6%) and cytokines/chemokines (6%) are the few approaches that used actual immunotherapy. They also found that about 80% of the microfluidic devices used in the papers they reviewed are manufactured using PDMS due to desirable properties such as transparency, low cost, gas permeability and elasticity.
Source: Microfluidic technologies for immunotherapy studies on solid tumors
